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Abstract
Porcine circovirus 2 (PCV2) has and is still causing important economic losses to pig industry. This is due to PCV2-systemic
disease (PCV2-SD), formerly known as postweaning multi-systemic wasting syndrome (PMWS), which increases mortality
rates and slows down the growth of the animals, as well as other conditions collectively included within the so-called
porcine circovirus diseases (PCVD). PCV2-SD affected pigs are considered to be immunosuppressed, with severe
lymphocyte depletion and evidence of secondary infections. However, PCV2-infected pigs not developing the
disease are able to mount humoral and cellular immune responses and clear the virus or limit the infection. On
the contrary, insufficient amounts of neutralizing antibodies have been linked to increased PCV2 replication,
severe lymphoid lesions and development of PCV2-SD. Central role in controlling PCV2 infection are played by
the antigen specific memory T cells. These cells persist long term post-infection or vaccination and are able to
expand rapidly after recall antigen recognition. Most farms in the main pig producing countries are applying
vaccination against PCV2 to prevent the disease and improve the farm performance. Vaccines do not induce
sterilizing immunity and PCV2 keeps on circulating even in farms applying vaccination. This, together with the high
mutation rate of PCV2, world-wide fluctuations in the genotype dominance and emergence of novel genetic variants,
warrant close molecular survey of the virus in the field.
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Background
Porcine circovirus 2-systemic disease (PCV2-SD),
formerly known as postweaning multisystemic wasting
syndrome (PMWS), causes important economic losses in
commercial pig farms due to increased mortality rates
and negative impact on the growth of the animals. Clin-
ical signs of PCV2-SD include wasting or decreased
weight gain, anaemia, diarrhoea and/or respiratory dis-
tress. Extensive lesions in lymphoid tissues due to deple-
tion of B and T lymphocytes of affected pigs can be
observed. Numbers of B- and T-cells are reduced both
in blood and lymphoid organs coinciding with the incre-
ment of macrophages/monocytes. Detailed description of
clinical signs and pathogenesis can be found elsewhere [1].
PCV2 is the necessary but not sufficient etiological agent
to trigger PCV2-SD, as well as other porcine circovirus
diseases (PCVD). The ubiquitous nature of PCV2 implies
that most of the animals worldwide get infected with this
virus, but just a proportion of them suffer from overt dis-
ease; therefore, most pigs suffer from a PCV2-subclinical
infection [2].
Since 2007, a number of commercial vaccines have
been launched significantly reducing the economic losses
due to PCV2 infection. Despite the vaccines, the virus is
still circulating even among vaccinated populations [3].
PCV2 has a circular single-stranded DNA genome of
1.7 kb with limited encoding capacity. Replication asso-
ciated proteins (Rep and Rep’) are encoded by ORF1, the
only structural capsid protein (Cap) is encoded by
ORF2, and ORF3 and ORF4 encode for proteins in-
volved in apoptosis and anti-apoptosis, respectively [4].
The capsid gene (cap) is the most used in phylogenetic
studies and four genotypes can be distinguished based
on it or complete PCV2 sequences, namely PCV2a,
PCV2b, PCV2c and PCV2d [5]. PCV2 is characterized
with high mutation rate, genotype dominance shifts and
a recent report suggests possible influence of vaccination
to its evolution [5–8].
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Under ideal conditions, immunological responses
against pathogens lead to their clearance and generation
of immunological memory. In contrast, pathogen evolu-
tion implies to develop strategies to circumvent and ex-
ploit the immune system to complete their life cycle.
Some pathogens, like PCV2, have the ability to persist in
the host, causing a prolonged pro-inflammatory state
leading to immunopathological effects. The outcome of
PCV2 infection varies greatly between individual pigs
and the ones developing a sufficient humoral and cellu-
lar immunity clear the infection. However, PCV2-SD af-
fected pigs develop severe lymphocyte depletion [9],
which was the first evidence for researchers that im-
munosuppression was the main feature of the disease.
Since then, there has been increasing amount of studies
about the involvement of the immune system in the
pathogenesis and the strategies PCV2 is using to
manipulate the immune cells for its benefit.
Immunomodulatory capacity of PCV2
Innate, non-adaptive host immune response is the early
barrier against pathogen infections. This response is acti-
vated immediately after invasion of a new pathogen. If
an early response does not lead to clearance of the
pathogen, the adaptive immune response takes place. In
the process of defence against pathogens, an important
role is played by dendritic cells (DC). DCs together with
macrophages are first immune cells to encounter patho-
gens. They are engulfing and digesting pathogens and
presenting antigens to T lymphocytes initiating the
adaptive immune arm. Two main types of dendritic cells
do exist: conventional DC (cDC) with the main role of
presenting antigens, and plasmacytoid DC (pDC) which
are potent producers of type I interferon (IFN) [10, 11].
As many other viruses, PCV2 is capable of modulating
the DC activity. PCV2 is engulfed by DC but does not
seem to actively replicate in these cells, neither is affect-
ing their survival [12, 13]. While cDC function is not
impaired by PCV2 accumulation, the pDC function is af-
fected by the virus [14, 15]. IFN-α is typically induced by
pDCs by many viruses and the best known function of
this cytokine is to induce an antiviral state. However,
PCV2 is down-regulating the induction of IFN-α in cul-
tured pDCs/monocytic cells, even in the presence of po-
tent IFN-α stimulators [14, 16]. In contrast, in vivo
infection with PCV2 has shown to induce IFN-α secre-
tion [17, 18]. Indeed, it has been shown that PCV2 can
have both immunostimulatory and inhibitory roles [19–
22]. Specifically, it has been demonstrated that the viral
genome, or parts of it, can modulate cytokine responses,
possibly via inhibitory /stimulatory CpG motifs interact-
ing with cytosolic or endosomal receptors in the cells
[19–21]. On the other hand, it has been suggested that
the balance between the levels of encapsulated genomic
ssDNA (stimulatory effect) and free dsDNA (inhibitory
effect) replicative forms of PCV2 determines the immu-
nomodulatory characteristics of PCV2 infection [22].
Another key cytokine which expression PCV2 infec-
tion seems to alter, is the tightly regulated, pleiotropic
cytokine IL-10. It can be produced by both innate
(macrophages, DC) and adaptive cells (B cells and sub-
sets of CD4+ and CD8+ cells). It is able to inhibit the
activity of several cell types involved in pathogen clear-
ance like macrophages, Th1 – and NK cells. The im-
portance of IL-10 during PCV2 infection has been
studied both in vivo and in vitro. IL-10 expression is in-
duced by PCV2, but not by non-pathogenic PCV1,
infection in vitro cultured PBMCs, especially the
monocyte/DC/macrophage populations [19, 23]. The
release of this cytokine by PCV2 infected PBMCs led to
inhibition of IFN-γ, IFN-α and IL-12 stimulated by re-
call antigen of another virus [19]. Monocyte/DC/
macrophage population was shown to be responsible of
the IL-10 production and whole non-inactivated virus,
but not Cap or Rep proteins, was identified as the trig-
gering viral signal [24]. Therefore, likely pathway for
IL-10 induction in this cell population is controlled
through Toll-like receptor 9 (TLR9), which is an endo-
somally expressed receptor recognizing unmethylated
DNA [25]. Transcription of IL-10 is also increased in
thymus of PCV2-SD affected pigs and this was associ-
ated with the thymic depletion and atrophy [26]. Sys-
temic IL-10 secretion has been associated with animals
evolving and suffering from PCV2-SD [17, 27]. Indeed,
it was suggested that IL-10 induction by PCV2 is a key
cytokine leading to immune disorders typically found
in PCV2-SD affected pigs. Furthermore, systemic IL-10
levels have been correlated with the viral load in blood
at 21 days post-infection [28]. Finally, the source and
impact of the IL-10 seen in the in vitro and in vivo
studies are supposedly very different considering that
these type of studies are conceptually very distinct: in
vitro assays allow detailed studies on the early onset of
cytokine secretion by identified innate cell types and in
vivo studies on the consequences of viral infection on
tissues and adaptive immune cells. However, IL-10 is to
be considered a cytokine affecting both innate and
adaptive immune responses and is one part of the puz-
zle leading to PCV2-SD.
Cellular and humoral immune responses against PCV2
Humoral immune responses against PCV2 infection
have been studied throughout the pig life from foetuses
to adult animals. This is due to the availability of simple
methods to measure distinct anti-PCV2 antibodies in
easily obtained serum samples and the intensive research
done in vaccines, which are based on the immunogenic
Capsid protein.
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Intra-uterine infection of PCV2 leads to antibody de-
velopment in foetuses. In utero infected foetuses can
mount humoral immune responses against PCV2 when
they are infected after day 70 of gestation [29, 30].
Lately, it was also shown that maternal antibodies may
leak through the placenta and those antibodies can be
detected in foetuses without evidence of viral infection
during gestation [31]. Indeed, the higher the dam anti-
PCV2 antibody titres, the higher the likelihood of anti-
body detection in its piglets. This finding has a practical
consequence about involvement of PCV2 infection in re-
productive failure cases, since antibodies can merely be
of maternal origin and not a real consequence of a foetal
virus infection. Therefore, care should be taken when
making conclusions about PCV2 foetal infection based
solely on serological tests [31]. However, this finding has
not been contrasted so far, and it would be important to
generate more data to confirm it.
After birth, piglets are protected against PCV2 infec-
tion due to the maternally derived neutralizing anti-
bodies present in the colostrum [32, 33]. These passively
acquired antibodies decline during the lactating and nur-
sery periods. Waning of maternal antibodies makes the
animals again susceptible to PCV2 infection followed by
active seroconversion [34–36]. Neutralizing antibodies
are efficient in clearing the virus from circulation and in-
sufficient amounts of neutralizing antibodies have been
linked to increased PCV2 replication, severe lymphoid
lesions and development of PCV2-SD [37, 38]. Interest-
ingly, during infection, antibodies are produced mainly
against the Cap protein but also against non-structural
Rep proteins. Anti-cap antibodies are produced earlier
and to a higher titre than anti-rep antibodies both in
healthy and PCV2-SD affected pigs [39, 40].
Recent studies have taken the cellular immune re-
sponses better into account than early studies. This is
mainly due to the notion that anti-PCV2 antibodies are
not always fully protective and cannot be used to predict
protection against PCV-SD [36, 41]. Cellular immunity,
especially development of IFN-γ secreting cells (SC), has
been inversely correlated with PCV2 viral loads in serum
[37, 42, 43]. Since PCV2 specific IFN-γ-SCs are T-cells
are able to produce IFN-γ upon stimulation with a recall
antigen, their assessment is used to measure the cell
mediated immunity and have been shown to increase
after PCV2 infection and vaccination [18, 44]. Interest-
ingly, IFN-γ-SCs are specific for both non-structural
Rep and structural Cap proteins [24]. PCV2-SD dis-
eased pigs suffer from B and T cell lymphopenia which
is induced by PCV2 infection. Most notably, B and
CD3 + CD4 + CD8+ memory/activated Th lymphocytes
are depleted and this depletion is related to the devel-
opment of PCV2-SD [45]. Both vaccination and infec-
tion elicit memory/activated Th cells [44, 46]. These
cells are activated, antigen specific T cells and memory
cells. Antigen specific memory T cells persist long term
post-infection/vaccination and are able to expand rap-
idly after recall antigen recognition, thus being able to
prevent PCV2 infection quickly [46]. More specifically,
it has been suggested that PCV2 specific IFN-γ/TNF-α
co-producing CD4+ cells, which are produced upon
vaccination/infection, play a central role in controlling
and clearing PCV2 infection [44]. Interestingly, this
subset of cells was induced in all PCV2 vaccinated/in-
fected animals, while specific antibodies were only de-
tected in nearly 45 % of these pigs [44]. Those results
further emphasize the importance of cellular immunity
in the control and clearance of PCV2 in infected
animals.
PCV2 evolution
Since the last 20 years, PCV2 is one of the most import-
ant swine pathogens. Currently, vaccines against PCV2
are widely used in commercial farms but since the vac-
cines do not induce sterilizing immunity, the virus keeps
circulating even in farms applying vaccination [3, 47].
This is further emphasized by the fact that transmission
of PCV2 among vaccinated pigs has an estimated
reproduction ratio (R0) of 1.5 versus 5.2 in non-
vaccinated pigs [48]. Since R0 measures the average of
secondary infections caused by an individual during its
infectious period, values of R0 > 1 represents that the
pathogen will be maintained within the population.
Therefore, PCV2 vaccination is very efficient in decreas-
ing infectious pressure, but not able to clear the virus
out from the farm.
Vaccines are based on the Cap protein or whole vi-
ruses. In the phylogenetic analysis cap gene is used to
classify PCV2 stains into four genotypes. The genetic
distance nowadays used to divide PCV2 into genotypes
is >3.5 % [49]. Until 2000 PCV2a was the most prevalent
genotype found in the field, but was replaced by the
PCV2b genotype coinciding with the most severe out-
breaks of PCV2-SD [8, 50, 51]. PCV2c was originally
found in Denmark and its frequency in field is very low
[5, 52]. Lately, PCV2d has emerged and it has been sug-
gested that a new shift in dominant genotype may be
on-going [5, 7, 53].
Origin of PCV2 is likely to be relatively recent, about
100 years ago [54]. It has been estimated that PCV2b
and PCV2d originated about 20 years ago, timing
which would fit to the worldwide emergence of PCV2-
SD [5, 54]. Within-genotype genetic divergence reflects
the time different genotypes have been circulating in
the pig population, PCV2a displaying the highest diver-
gence, followed by PCV2b and PCV2d [5]. Whole ge-
nomes between genotypes differ from approximately
8 % to 12 %, PCV2c being the most distinct and
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followed by PCV2d [5]. Different genotypes’ Capsid
protein amino acid sequences differ from 6 % to 15 %.
The variability of PCV2 is created by the high evolution-
ary rates being 1.2x10−3 substitution/site/year, resembling
the one from RNA viruses, and recombination [54–58].
Selection which works on the variants is further shaping
the evolution of PCV2. Indeed, due to mutations in the
cap gene, new antigenic variants have emerged [59–61].
Furthermore, applying next-generation-sequencing tech-
nology, low frequency mutations have been identified [6].
Low frequency mutants are unfit in the given environment
but form reservoirs allowing fast adaptation of the virus in
changing environments. On the other hand, sometimes
unexpected, beneficial mutations may occur and quickly
increase their frequencies in virus population [6].
The rep gene is highly conserved while the cap gene
contains more variability. It has been shown that poly-
clonal sera from individual pigs can have different titres
of neutralizing antibodies against isolates from the same
genotype [62]. Indeed, even single mutations may lead
to antigenically distinct viruses as shown by studies
using monoclonal antibodies to subtype PCV2 strains
[63, 64]. These results are not surprising for a virus like
PCV2 since it has high evolution rate and infection is
highly prevalent under field conditions. However, it is
to bear in mind that biological differences, like
neutralization by antibodies, are not correlated with the
virus sequence but rather depend on the specific virus
isolate. Several linear (within the residues 25–43, 69–83,
113–127, 117–131, 169–183 and 193–207) and conform-
ational (within residues 47–85, 165–200 and 230–233)
epitope domains have been identified in the Cap protein
[64–66]. It has been shown that these regions contain po-
sitions which are under negative and positive selection.
Especially, non-conserved positions were found to be
under positive selection, which can be considered sites tar-
geted by host immune system [59, 67]. Conserved
domains in PCV2 proteins are essential sites for their
functionality and any mutation in these sites are non-
viable for the virus.
One of the current challenges is to understand the
long-term effect of vaccination on PCV2 evolution. The-
oretically, there are several aspects which suggest that
current vaccines could shape the evolution of PCV2.
Vaccination is widely applied, covering more than 90 %
of the animals in important pig producing countries like
USA, Germany and Spain. Pig densities in herds are
high, therefore allowing quick spread of any infectious
agent. Furthermore, PCV2 is circulating despite vaccin-
ation, since vaccines do not prevent PCV2 infection. In-
deed, it has been already shown that PCV2 populations
found in vaccinating and non-vaccinating farms differ in
its genomic composition [6]. Also, emerging PCV2d iso-
lates have been found in vaccinated pigs suffering from
PCV2-SD. However, in experimental infection it was
shown that current vaccine based on PCV2a is effective
against PCV2d [68]. More work is needed to study the ef-
fect of vaccination in virus evolution; especially in the
cases of disease appearance in vaccinated animals, since it
is unclear if vaccination or vaccine has failed (vaccination
vs. vaccine failure).
Conclusions
It is known that most of the pigs mount effective im-
mune responses to clear or limit PCV2 infection. How-
ever, a proportion of pigs may not be able to counteract
the infection and develop disease. Nowadays, the dis-
ease burden can be controlled by efficient vaccination.
Vaccination is priming the immune system and allows
its quick and effective activation when encountering
PCV2. Since vaccines are not able to completely avoid
PCV2 infection, and considering the mutation capacity
of the virus, further phylogenetic evolution of PCV2 in
the vaccination scenario is guaranteed.
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